Latest Articles
Endometrial Cancer Remission Rate: What Patients Need to Know in 2025 - Oncodaily
Endometrial Cancer Remission Rate: What Patients Need to Know in 2025 Oncodaily
Published: Dec. 7, 2025, 4:41 p.m.
AQB improves carboplatin sensitivity in endometrial cancer through dual DNA repair modulation: suppression of the p21-E2F1-RAD51 and ATF3-HDAC1-BRCA1 signaling - Nature
AQB improves carboplatin sensitivity in endometrial cancer through dual DNA repair modulation: suppression of the p21-E2F1-RAD51 and ATF3-HDAC1-BRCA1 signaling Nature
Published: Dec. 6, 2025, 7:16 p.m.
Advancing Care in Endometrial Cancer: Exploring Long-Term Outcomes and Real-World Evidence - OncLive
Advancing Care in Endometrial Cancer: Exploring Long-Term Outcomes and Real-World Evidence OncLive
Published: Dec. 5, 2025, 1 p.m.
Bayer Aims To Broaden Mirena’s Use With Phase III Endometrial Hyperplasia Study - Citeline News & Insights
Bayer Aims To Broaden Mirena’s Use With Phase III Endometrial Hyperplasia Study Citeline News & Insights
Published: Dec. 4, 2025, 11:19 a.m.
The Impact of Hormone Replacement Therapy on Endometrial Pathology: A Retrospective Observational Study - Cureus
The Impact of Hormone Replacement Therapy on Endometrial Pathology: A Retrospective Observational Study Cureus
Published: Dec. 4, 2025, 4:59 a.m.
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia - BioSpace
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia BioSpace
Published: Dec. 3, 2025, 2:11 p.m.
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia - sharewise.com
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia sharewise.com
Published: Dec. 3, 2025, 5:04 a.m.
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia - Business Wire
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia Business Wire
Published: Dec. 2, 2025, 1:05 p.m.
Bayer (BAYRY) starts SUNFLOWER Phase III Mirena trial for nonatypical endometrial hyperplasia - Stock Titan
Bayer (BAYRY) starts SUNFLOWER Phase III Mirena trial for nonatypical endometrial hyperplasia Stock Titan
Published: Dec. 2, 2025, 1:05 p.m.
Bayer starts phase III study with Mirena for treatment of nonatypical endometrial hyperplasia - MarketScreener
Bayer starts phase III study with Mirena for treatment of nonatypical endometrial hyperplasia MarketScreener
Published: Dec. 2, 2025, 7:36 a.m.
Link copied to clipboard!